For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Za ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? IQVIA Holdings (IQV) , which belongs to the Zacks Medical - Instruments industry, could be a great candidate to consider.This clinical testing company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 1.70%.For the most recent quarter, IQVIA was ...

IQVIA Holdings Inc. (IQV) is benefiting from its ability to standardize, organize and integrate data through analytics and global technology, which boosts its client base. Shareholder-friendly policy is another green flag for investors. Meanwhile, competitive pressure is troublesome and low liquidity poses a threat to the company’s ability to pay off short-term debt.IQV reported impressive third-quarter 2024 results. Adjusted earnings were $2.8 per share, outpacing the Zacks Consensus Estimate by 1.1% and r ...

IQVIA Holdings (IQV) shares rallied 3% in the last trading session to close at $197.27. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.1% loss over the past four weeks.The stock has recorded the price rise as the company’s short-cycle businesses continue to improve on the back of its clients’ launching drugs and executing critical commercial programs.This clinical testing company is expected to post quarte ...

Join Compounding Healthcare where we employ data analytics in combination with technical analysis and clinical data breakdown in order to manage a position in numerous potential multi-bagger investments that can grow into a comprehensive healthcare portfolio.It has been roughly 10 months from my previous article on IQVIA Holdings (NYSE: IQV ), where I discussed the company's Q4 2023 marks, which beat the Street's expectations thanks to record revenues and EPS growth. At that time, IQVIA publicizedHe is the ...

While IQVIA Holdings Inc. (IQV) benefits from its market leadership, data-driven innovation, and global expansion, it must navigate pricing pressure.IQV has an expected long-term (three to five years) EPS growth rate of 9.6%. The company’s earnings for 2024 and 2025 are expected to grow 9% and 6.9%, respectively.IQV’s Global Reach, Market Leadership in Healthcare AnalyticsIQVIA operates in over 100 countries, giving it a vast global footprint. This extensive presence enables it to tap into emerging markets ...

For the quarter ended September 2024, IQVIA Holdings (IQV) reported revenue of $3.9 billion, up 4.3% over the same period last year. EPS came in at $2.84, compared to $2.49 in the year-ago quarter.The reported revenue represents a surprise of +1.11% over the Zacks Consensus Estimate of $3.85 billion. With the consensus EPS estimate being $2.81, the EPS surprise was +1.07%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street e ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-35907 __ ...

Financial Data and Key Metrics - Revenue for Q3 2024 grew 4.3% on a reported basis and 4.2% at constant currency, with COVID-related revenues at $20 million, down from $100 million in Q3 2023 [34] - Adjusted EBITDA increased 5.7% in Q3, driven by revenue growth and cost management, resulting in 30 bps of margin expansion [20] - Adjusted diluted EPS for Q3 was $2.84, up 14.1% year-over-year [20] - Backlog reached a record $31.1 billion, up 8% year-over-year, with next 12 months revenue from backlog up 5.5% [17][38] - Free cash flow for Q3 was $571 million, with $200 million spent on share repurchases [40] Business Line Performance - Technology & Analytics Solutions (TAS) revenue grew 8.6% reported and 8.2% at constant currency, with organic growth in mid-single-digits [35][68] - R&D Solutions (R&DS) revenue grew 1.9% reported and 2% at constant currency, with 6% growth excluding COVID-related work [35] - Contract Sales and Medical Solutions (CSMS) revenue declined 1.6% reported and 1.1% at constant currency [35] Market Performance - Biotech funding reached $16 billion in Q3, with year-to-date funding over $80 billion, representing more than 50% growth year-over-year [16] - RFP flow increased mid-single digits year-over-year, with qualified pipeline growing low double-digits overall [17][18] Strategic Direction and Industry Competition - The company successfully renewed all large pharma strategic partnerships and expanded relationships with over half a dozen clients [14][15] - The launch of IQVIA AI Assistant, a generative AI tool, aims to provide life science customers with real-time insights [27][28] - The company continues to differentiate in oncology, with several leading sponsors selecting IQVIA for global Phase III studies [23][24] Management Commentary on Operating Environment and Future Outlook - The near-term market environment for clinical trials remains choppy, with aggressive competitive pricing and higher-than-normal cancellations due to the IRA [11] - The company expects TAS to grow approximately 6% and R&DS to grow 5% for the full year, both at constant currency and excluding COVID-related impacts [43] - Management anticipates mid-single-digit growth for 2025, with TAS expected to grow around 6% and R&DS around 5% [50][51] Other Important Information - The company updated its full-year guidance due to delays in two mega trials, now expecting revenue between $15.350 billion and $15.400 billion, adjusted EBITDA between $3.675 billion and $3.7 billion, and adjusted diluted EPS between $11.10 and $11.20 [42] - The company plans to provide preliminary 2025 guidance at its Investor Day on December 10th [48] Q&A Summary Question: Thoughts on preliminary 2025 growth expectations? - The company expects mid-single-digit growth for 2025, with TAS growing around 6% and R&DS around 5% [50][51] Question: Details on trial delays and confidence in resumption? - The delays are due to client-related logistical issues, unrelated to financials or drug futility, and the trials are expected to resume in 2025 [55][56][60] Question: Timing and impact of cancellations on 2025? - Cancellations are split between reprioritization and drug futility, with reprioritization expected to peak by the end of 2024 [61][62] - Delays in trials will affect sequential growth but are not expected to be incremental to 2025 [65][66] Question: M&A strategy and financial profile? - The company spent $649 million on acquisitions year-to-date, with a focus on small deals, and expects to continue deploying capital for acquisitions and share repurchases [68][69][75] Question: Pricing pressure and cost management? - Pricing pressure is tough across the board, particularly in FSP, and the company is managing costs while navigating delays and cancellations [81][82][91] Question: Strategic partnerships and interest expense? - The company has largely completed strategic partnership renewals and expects interest expense for 2024 to be around $625 million [94][96] Question: Conditions for R&DS growth in 2025? - Growth expectations for R&DS in 2025 are based on the resumption of delayed trials and the end of program reprioritizations [101][102]

IQVIA Holdings Analytics Inc. (IQV) has reported impressive third-quarter 2024 results, wherein earnings and revenues beat the Zacks Consensus Estimate.See Zacks Earnings Calendar to stay ahead of market-making news.Adjusted earnings were $2.8 per share, outpacing the Zacks Consensus Estimate by 1.1% and rising 14.1% on a year-over-year basis. Total revenues of $3.9 billion surpassed the consensus estimate by 1.1% and grew 4.3% from the year-ago quarter.The IQV stock has gained 20% over the past year, under ...